|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||119.54 - 121.71|
|52-week range||91.51 - 122.16|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||37.56|
|Forward dividend & yield||1.60 (1.35%)|
|Ex-dividend date||12 Aug 2022|
|1y target est||N/A|
Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy